Treatment of growth hormone deficiency with growth hormone receptor agonists or insulin-like growth factor 1 (IGF-1) improves comorbid MASLD (70) and treating patients with MASLD (without growth hormone deficiency) with recombinant growth hormone improves hepatic steatosis (71). Here, GHR is linked to metabolic dysfunction-associated steatotic liver disease.